Conditions: Hepatitis B, Chronic
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 228
Healthy volunteers: no

Brief summary:
Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir

Detailed description:

Arms:
arm 1: None arm 2: Control

Interventions: intervention 1: Entecavir intervention 2: Adefovir/Entecavir
Intervention descriptions: intervention 1: Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks intervention 2: Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks

Protocol document: